Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Cyclin D/Cdk4"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Karen Kelly, Lincoln Nadauld, Vivek Subbiah, Davendra Sohal, Howard Safran, Julio Antonio Peguero, Alejandro D. Ricart, Erica Stealey, Juneko E. Grilley-Olson, Das Purkayastha, Joseph Paul Eder, Bert H. O'Neil, Barinder P. Kang
Publikováno v:
JCO precision oncology. 3
PURPOSE As part of the Novartis Signature Program, this study evaluated the efficacy of ribociclib (selective cyclin-dependent kinase 4/6 [CDK4/6] inhibitor) in patients with cyclin D–CDK4/6 pathway–aberrant tumors. METHODS This was a phase II, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25f7aeae9699bf59c9b2753a2c6e2410
https://pubmed.ncbi.nlm.nih.gov/35100715
https://pubmed.ncbi.nlm.nih.gov/35100715
Publikováno v:
Oncogene
The retinoblastoma protein (RB) restricts cell cycle gene expression and entry into the cell cycle. The RB-related protein p130 forms the DREAM (DP, RB-like, E2F, and MuvB) complex and contributes to repression of cell cycle-dependent genes during qu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fc05f954df33e54ad78e578064f0df2
https://doi.org/10.1038/s41388-019-0767-9
https://doi.org/10.1038/s41388-019-0767-9
Publikováno v:
Toxicology and Applied Pharmacology. 366:75-82
Bisphenol S (BPS), exhibiting estrogenic activity, has been reported to promote cell proliferation in MCF-7 breast cancer cells; however, the underlying mechanism remains unclear. In this study, BPS (1–100 μM) significantly promoted cell prolifera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60cb4639ea153643dd6e9aea91d925cc
https://doi.org/10.1016/j.taap.2019.01.017
https://doi.org/10.1016/j.taap.2019.01.017
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Since their discovery as drivers of proliferation, cyclin-dependent kinases (CDKs) have been considered therapeutic targets. Small molecule inhibitors of CDK4/6 are used and tested in clinical trials to treat multiple cancer types. Despite their clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feacd97d61f910412ff2408501f76e21
http://europepmc.org/articles/PMC8184839
http://europepmc.org/articles/PMC8184839
The mammalian cell cycle is driven by a complex of cyclins and their associated cyclin-dependent kinases (CDKs). Abnormal dysregulation of cyclin-CDK is a hallmark of cancer. D-type cyclins and their associated CDKs (CDK4 and CDK6) are key components
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd87a9d2952db24f22aaca80f483d3a9
https://doi.org/10.1016/bs.acr.2020.02.002
https://doi.org/10.1016/bs.acr.2020.02.002
Autor:
Yingxia Peng, Suihai Wang, Ningning Dong, Yanjun Gao, Xiaobo Wang, Qian Xie, Ying-Song Wu, Ming Li, Ji-Liang Li, Xian Zhang
Publikováno v:
The Journal of Pathology
RN181, a RING finger domain‐containing protein, is an E3 ubiquitin ligase. However, its biological function and clinical significance in cancer biology are obscure. Here, we report that RN181 expression is significantly down‐regulated in 165 tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35840923c54fadaf44ae6ab2a1f15f84
https://pubmed.ncbi.nlm.nih.gov/30714150
https://pubmed.ncbi.nlm.nih.gov/30714150
Autor:
Josh Stewart, Brian Eastman, Lauren Sitts, Heekyung Chung, Chi Ching Mak, Steven Cha, Timothy Phalen, Sunil Kc, Carine Bossard, Chu-Chiao Wu
Publikováno v:
Cancer Research. 80:6401-6401
Dysregulation of the cyclin D-CDK4/6-RB signaling axis is implicated in HR+ breast cancer (BC). While CDK4/6 inhibitors such as palbociclib (Palbo) have shown efficacy in this cancer type, overcoming resistance to these agents is an unmet need for pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b57d8a1169aa5663b29e5ca90192dc3
https://doi.org/10.1158/1538-7445.am2020-6401
https://doi.org/10.1158/1538-7445.am2020-6401